Recruiting
Phase 1
Phase 2

HS235

Sponsor:

35Pharma Inc

Code:

NCT07123779

Conditions

Pulmonary Hypertension

Heart Failure With Preserved Ejection Fraction

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

HS235

Placebo

Study Details

Brief summary:

Study of HS235 in Obese Participants with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction

Conditions

Pulmonary Hypertension

Heart Failure With Preserved Ejection Fraction

Study ID

NCT07123779

Start date

Aug, 2026

Status verified date

Aug, 2026

Completion date

Jan, 2030

Anticipated

Primary completion date

Jan, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Participants are eligible to be included in the study only if they meet at least all the following criteria:

1. Male or female, ≥ 18 years of age.
2. \[Sub-population A only - using a remote PAP sensor\]- Ambulatory PAP monitoring (e.g., CardioMEMS™ HF System or Cordella™ HF System) implanted in the course of standard of care at least 90 days before Screening.

Hemodynamic evidence of PH with:
1. mPAP ≥ 25 mm Hg, as measured in supine position by the averaged 7-day values (weekly average) 2 weeks and 1 week before Randomization AND,
2. dPAP ≥ 15 mm Hg, as measured in supine position by the averaged 7-day values (weekly average) 2 weeks and 1 week before Randomization.
3. \[Sub-population B only - without a remote PAP sensor\]

Hemodynamic evidence of PH based on the presence of all the following RHC parameters obtained during the Screening period, prior to randomization:
1. PVR ≥ 240 dyn\*sec/cm5 or ≥ 3 WU, and
2. mPAP > 20 mmHg, and
3. PAWP > 15 mmHg but < 30 mmHg, and
4. dPAP ≥ 15 mmHg.
4. Established diagnosis of HFpEF with left ventricular ejection fraction (LVEF) ≥ 45 % as measured by echocardiography during Screening and and no documented LVEF < 45% during the 2 years preceding Screening..
5. New York Heart Association (NYHA) class II or III heart failure symptoms.
6. Stable diuretic regimen during the screening period.
7. Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) < 90 at screening.
8. 6-minute walking distance (6MWD) ≥ 100 m at screening.
9. Body mass index ≥ 30 to ≤ 50 kg/m2 and Body weight ≤140 kg.
10. Ability to adhere to study visit schedule and understand and comply with all protocol requirements.

Exclusion Criteria:

1. Hospitalization for any worsening medical condition or major surgery within 4 weeks prior to screening.
2. Occurrence of an acute coronary syndrome, percutaneous coronary intervention, or cardiac surgery within 90 days prior to Screening.
3. Implantation of a cardiac resynchronization therapy (CRT) device within 90 days before screening.
4. Planned cardiovascular revascularization or planned implantation of CRT device.
5. History of heart transplant or on heart transplant list.
6. History of serious or life-threatening cardiac arrhythmia within 90 days prior to screening.
7. Systemic hypotension or uncontrolled systemic hypertension.
8. History of Pericardial constriction or hypertrophic cardiomyopathy.
9. History of significant valvular stenosis or regurgitation.
10. Participants with a pneumonectomy or more than moderate Chronic Obstructive Pulmonary Disease (COPD) or mild interstitial lung disease (ILD) or mild obstructive sleep apnea (OSA).

Study Design

Enrollment

126 participants

Anticipated

Allocation

Randomized

Intervention Model

Sequential

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Investigational Product

HS235 Subcutaneous Injection

placebo comparator: Placebo

Subcutaneous Injection

Interventions

HS235

Subcutaneous Injection

Placebo

Subcutaneous Injection

Primary outcome measure

  • Incidence and Number of Adverse Events (AEs) [ Time Frame: Up to 24 weeks ]

Central Contacts and Locations

Central contacts

US GSK Clinical Trials Call Center

877-379-3718GSKClinicalSupportHD@gsk.com

EU GSK Clinical Trials Call Center

+44 (0) 20 89904466GSKClinicalSupportHD@gsk.com

Locations

Investigational Site-101

Recruiting

Greenville, South Carolina, United States, 29605

More Information

Sponsor

35Pharma Inc

Last update posted

Aug 17, 2026

Last verified

Aug, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by 35Pharma Inc on 2026-08-17.